Paratek Pharmaceuticals Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Paratek Pharmaceuticals stock.
View analyst ratings for Paratek Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Paratek Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Paratek Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Paratek Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Paratek Pharmaceuticals.

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) posted its quarterly earnings results on Monday, May, 17th. The specialty pharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by $0.17. The specialty pharmaceutical company had revenue of $16.43 million for the quarter, compared to analyst estimates of $32.83 million.
View Paratek Pharmaceuticals' earnings history.

Paratek Pharmaceuticals' stock was trading at $3.89 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PRTK shares have increased by 90.0% and is now trading at $7.39.
View which stocks have been most impacted by COVID-19.

4 brokerages have issued 12 month price objectives for Paratek Pharmaceuticals' shares. Their forecasts range from $10.00 to $22.00. On average, they anticipate Paratek Pharmaceuticals' share price to reach $15.25 in the next twelve months. This suggests a possible upside of 106.4% from the stock's current price.
View analysts' price targets for Paratek Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to Paratek Pharmaceuticals include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly and (LLY), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT) and Supernus Pharmaceuticals (SUPN).
View all of PRTK's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Paratek Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), CBL & Associates Properties (CBL), Inovio Pharmaceuticals (INO), ADMA Biologics (ADMA), Aduro Biotech (ADRO), Corbus Pharmaceuticals (CRBP) and Rigel Pharmaceuticals (RIGL).

Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."

Paratek Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.41%), Rock Springs Capital Management LP (3.59%), General American Investors Co. Inc. (2.10%), Geode Capital Management LLC (1.48%), Renaissance Technologies LLC (1.29%) and Northern Trust Corp (1.04%). Company insiders that own Paratek Pharmaceuticals stock include Adam Woodrow, Evan Loh, Michael Bigham, Randall B Brenner and William M Haskel.
View institutional ownership trends for Paratek Pharmaceuticals.

PRTK stock was sold by a variety of institutional investors in the last quarter, including D. E. Shaw & Co. Inc., Renaissance Technologies LLC, Weil Company Inc., Northern Trust Corp, Stifel Financial Corp, Essex Investment Management Co. LLC, Los Angeles Capital Management LLC, and General American Investors Co. Inc.. Company insiders that have sold Paratek Pharmaceuticals company stock in the last year include Adam Woodrow, Evan Loh, Michael Bigham, Randall B Brenner, and William M Haskel.
View insider buying and selling activity for Paratek Pharmaceuticals or view top insider-selling stocks.

PRTK stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, CM Management LLC, Perkins Capital Management Inc., Geode Capital Management LLC, New York State Common Retirement Fund, BlackRock Inc., Barclays PLC, and XTX Topco Ltd.
View insider buying and selling activity for Paratek Pharmaceuticals or or view top insider-buying stocks.

Shares of PRTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PRTK stock can currently be purchased for approximately $7.39.

Paratek Pharmaceuticals has a market capitalization of $346.80 million and generates $46.92 million in revenue each year. The specialty pharmaceutical company earns $-96,540,000.00 in net income (profit) each year or ($2.14) on an earnings per share basis.

Paratek Pharmaceuticals employs 196 workers across the globe.

The official website for Paratek Pharmaceuticals is www.paratekpharma.com.

Paratek Pharmaceuticals is headquartered at 75 PARK PLAZA, BOSTON MA, 02116.

Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The specialty pharmaceutical company can be reached via phone at 617-807-6600 or via email at [email protected]